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1. Introduction 
Human melanoma is the deadliest form of skin cancer in the world, and its incidence is 
rapidly increasing every year 3-7% on average of the last decades, pointing to melanoma as 
one of the biggest health problem worldwide (Perlis & Herlyn, 2004). Recent statistics show 
that melanoma represents 1-3% of all malignant tumors, with Australia and New Zealand 
having the highest incidence (40 new cases/100 000 inhabitants per year), followed by North 
European countries and the USA; on the other hand, Japan and central Africa share the 
lowest incidence. Melanoma is one of the most aggressive tumors. Up to one-fifth of patients 
progress to metastatic (stage IV) disease, with a median survival of 6 months and a 5-year 
survival rate of less than 5% (Balch et al., 2001). Melanoma is resistant to conventional 
therapy such as chemotherapy, radiotherapy and immuno-therapy, as only 5-20% of the 
patients show a positive response to these treatments. To date, the only FDA-approved 
chemotherapy for melanoma is the alkylating agent dacarbazine (DTIC), which gives clinical 
responses in 5–10% of patients and cures in about 1%. The only other approved agents for 
disseminated melanoma are interleukin (IL)-2 and interferon (IFN)-a, which also have low 
response rates. During the radial phase, melanoma cells spread horizontally, while during 
the vertical phase they are able to invade the dermis and become able to generate metastasis 
(Garbe et al., 2011). Usually, the two phases represent the step-process that leads to 
aggressive melanomas: once melanoma has spread beyond its original location, it is usually 
highly resistant to therapies. There are four major types of melanoma: superficial melanoma, 
the most common type, flat and irregular in shape and colour, nodular melanoma, lentigo 
maligna melanoma, usually occuring in the elderly, and finally, acral lentiginous melanoma, 
the least common form of melanoma, which develops at high incidence in African 
Americans. Melanomas may develop in or near a previously existing precursor lesion or in 
healthy skin, and they can appear in the mouth, eye, or retina at the back of the eye, vagina, 
esophagus, anus, urinary tract, and small intestine. Age, sunburns during childhood, close 
relatives with a history of melanoma, presence of displastyc moles, weak immune-system, 
long-term exposure to sunlight and exposure to carcinogens are the most common risk 
factors for melanoma development. Melanoma originates from mutated melanocytes, which 
share with neurons a common neuroectodermal origin. Among the molecules that act as 
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neurotrophic factors, neurotrophins (NTs) and their receptors constitute an important 
network. 
2. Neurotrophins 
NTs are a family of structurally and functionally related proteins, initially identified as 
promoters for neuronal survival. During a search for survival factors, nerve growth factor 
(NGF) was initially identified (Levi-Montalcini, 1987). Secondly, brain-derived neurotrophic 
factor (BDNF) was characterized as a survival factor for several neuronal populations not 
responsive to NGF (Barde et al., 1982). These two proteins revealed conserved features of 
the sequences, leading to isolation of clones encoding additional members of this family. NT 
expressed in mammals are four: NGF, BDNF, neurotrophin-3 (NT-3) and NT-4. NTs play a 
critical role in developmental neurobiology; they are crucial in cellular interactions, in 
regulating synapse formation and plasticity (Huang et al., 2003), in controlling cell survival 
and differentiation (Segal, 2003). NTs effects are mediated by two classes of cell-surface 
receptors, a family of tyrosine kinase receptors called Trks (TrkA, TrkB and TrkC) and the 
p75 neurotrophin receptor (p75NTR). Trk receptors bind NTs with higher affinity and 
specificity. In particular, TrkA binds NGF and NT-3, TrkB binds BDNF, NT-3, NT-4/5. TrkC 
only binds NT-3. On the other hand, p75NTR binds all NTs with low affinity and specificity. 
 
 
Fig. 1. NTs and their receptors 
Trks are tyrosine kinase receptors with similar structure. They are activated by ligand-
induced formation of noncovalently associated receptor dimers. In addition to the three full-
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length Trk proteins, all three trk genes encode other protein isoforms by alternative splicing 
in the extracellular and intracellular domains, which include insertions in the extracellular 
domain (Barker et al., 1993; Tacconelli et al., 2005) and deletions or added residues in the 
intracytoplasmic domain (Reichardt, 2006). Several different mutation types in the trkA gene 
have been identified in congenital insensitivity to pain with anhydrosis (CIPA) patients 
(Indo, 2001). The phenotypes associated with CIPA are believed to result in large part from 
loss of NGF-dependent neurons, including nociceptive sensory and sympathetic neurons, 
during embryogenesis. A dominant mutation in TrkB (Y722C) that impairs TrkB kinase 
signalling has recently been described in a patient with severe hyperphagic obesity and 
severe impairments in nociception, learning and memory (Yeo et al., 2004). 
The biological effects induced by NTs strongly depend on the pattern of NT receptor/co-
receptors expression in target cells as well as onset of intracellular adaptor molecules that 
link NT signaling to different biochemical pathways. The propensity of NTs to produce 
diametrically opposing effects on cell survival has led to propose a “yin and yang” model of 
neurotrophin action, where the binary actions of NTs depend on both the form of the 
neurotrophin (pro- versus mature) and the class of receptor that is activated (Lu et al., 2005). 
Central to the proposed “yin–yang” model of NTs function is the observation that a mature 
NT binds preferentially to Trk receptors to enhance cell survival, whereas an unprocessed 
proNT binds to p75NTR to induce cell death. NTs interaction with Trks require receptor 
dimerization, autophosphorylation, and the subsequent binding of adaptor molecules that 
couple Trk receptors to different intracellular signal transduction pathways (Reichardt, 
2006). NTs interact with trks receptors at the membrane-proximal immunoglobulin-like 
domain. The three-dimensional structures of this domain in each of the Trk receptors have 
been solved (Ultsch et al., 1999). Expression of a specific Trk receptor confers responsiveness 
to the NT to which it binds. On the other hand the isoform of TrkA including an insert is 
also activated by NT-3 in addition to NGF (Clary & Reichardt, 1994), while the similar 
isoform of TrkB is activated by NT-3 and NT-4 in addition to BDNF (Strohmaier, 1996). 36 
novel isoforms of TrkB proteins with unique properties have been described recently. This 
suggests high complexity in the synthesis, regulation and function of this important NTs 
receptor, emphasizing the need for further study of these novel TrkB variants (Luberg et al., 
2010). TrkC has several characteristics of a tumor suppressor: its expression in tumors has 
often been associated with good prognosis. It was recently demonstrated to be a dependence 
receptor, transducing different positive signals in the presence of ligand but inducing 
apoptosis in the absence of ligand. (Tauszig-Delamasure et al., 2007). Differential splicing of 
trkC mRNA also results in expression of a TrkC isoform with an amino acid insert within 
the tyrosine kinase domain. This insert appears to modify the substrate specificity of this 
tyrosine kinase, inhibiting activation of several substrates and interfering with its ability to 
promote neuronal differentiation (Guiton et al. 1995). 
p75NTR was the first NT receptor to be identified as a low-affinity receptor for NGF, but it 
was subsequently shown to bind each of the neurotrophins with a similar affinity 
(Rodriguez-Tébar et al., 1990; Frade & Barde, 1998). p75NTR belongs to the tumor necrosis 
factor receptor superfamily. It has an extra-cellular domain containing four cysteine-rich 
motifs, a single transmembrane domain and a cytoplasmic domain that includes a ‘death’ 
domain, similar to those present in other members of this family (He & Garcia, 2004). This 
receptor does not contain a catalytic motif, however it interacts with proteins that transmit 
crucial signals for regulating neuronal survival and differentiation as well as synaptic 
plasticity. The three-dimensional structure of the extracellular domain of p75NTR in 
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association with an NGF dimer indicates that each of the four cysteine-rich repeats 
participates in binding to NGF (He & Garcia, 2004). The binding of NGF to p75NTR may 
result in dissociation of p75NTR multimers and is compatible with the possibility that Trk 
and p75NTR monomers simultaneously bind the same NT dimer. A gene related to 
p75NTR, named NRH-2, has recently been identified. The product of this gene lacks the 
extracellular cysteine-rich repeats present in p75NTR and fails to bind NGF, but it is able to 
interact and influence the ligand-binding properties of TrkA (Murray et al., 2004). When 
p75NTR is expressed alone, mature NTs are capable of inducing apoptosis or promote 
survival depending on the intracellular adaptor molecules present in target cells by 
interacting with a mounting number of downstream molecules (Wang et al., 2000). 
However, signaling through p75NTR may also promote cell survival acting through the NF-
κB pathway (Roux & Barker, 2002). The coexpression of Trks and p75NTR increases high 
affinity NT binding, enhances Trk ability to discriminate a preferred ligand from the other 
NT, and promotes NT survival effects (Teng & Hempstead, 2004). On the other hand, the 
proform of NT, proNGF, binds p75NTR in association with its co-receptor sortilin, but not 
Trk (Nykjaer et al., 2004). More specifically, sortilin, a member of the vps-10 protein family, 
binds the ‘‘pro’’ region of NGF, whereas p75NTR binds mature NGF. The p75NTR–sortilin 
complex couples with proNGF to induce apoptosis (Kaplan & Miller, 2004). 
3. NTs and skin microenviroment 
NTs also operate in a number of non-neuronal tissues, including skin where a complex NT 
network exists with various cells that are either the target or the source of NTs, thus playing 
autocrine and paracrine functions (Botcharev et al., 2006). Moreover, given the common 
neuroectodermal origin of the skin with the nervous system, different studies have been 
carried out on the role of NTs and their receptors in the cutaneous system. First, NGF, which 
is synthesized in the epidermis, is retrogradelly transported to the ganglia to stimulate the 
release of neuropeptides in the skin, thus favoring cutaneous neurogenic inflammation 
(Davis et al., 1997). Moreover, null mutations of genes in the NTs and their receptors lead to 
loss/reduction of specific neurons in sensory ganglia; conversely, cutaneous overexpression 
of NTs results in skin hyperinnervation and increase in the number of sensory neurons 
innervating the skin (Montaño et al., 2010). Not only NGF is neurotrophic at the skin level, 
but it possesses a number of biological effects also in cutaneous cells. Normal human 
keratinocytes synthesize and release NGF that can act as a growth factor for these cells 
(Pincelli et al., 1994). The most common type of skin cells is the keratinocyte. These cells 
synthesize and secrete all NTs (Di Marco et al., 1991), NGF being secreted at highest levels 
as compared to the other NT. In human keratinocytes, NT-3 and NGF upregulate each 
other’s secretion. UVB irradiation downregulate NGF, while UVA augment NT-3 release 
(Marconi et al., 1999; Stefanato et al., 2003). Human keratinocytes release NGF in increasing 
amounts while proliferating, whereas secretion ends in more differentiated cells (Pincelli et 
al., 1994). NGF induces human keratinocyte proliferation (Di Marco et al., 1993) and it can 
either stimulate or inhibit murine epidermal and hair follicle keratinocyte proliferation in 
situ (Paus et.al., 1994). Human keratinocytes express the high affinity receptors TrkA and 
TrkC, but not the functional form of the TrkB (Marconi et al., 2004). Endogenous NGF 
autocrinally sustains keratinocyte proliferation. NTs together with their receptors TrkA and 
TrkB can stimulate proliferation of mouse keratinocyte in ex-vivo cultured skin explants 
(Paus et al., 1994; Botchkarev et al., 1999). Moreover, NTs modulate susceptibility to 
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apoptosis in the epidermis. Autocrine NGF protects human keratinocytes from UVB-
induced apoptosis, while UVB downregulates both NGF and TrkA expression in these cells 
(Marconi et al., 1999). Because in normal human keratinocytes TrkB lacks functional isoform, 
NT may exert different functions by binding p75NTR alone. In this context, p75NTR acts as 
a proapoptotic receptor. This is exemplified by BDNF and NT4, which induce a higher rate 
of apoptosis in normal human keratinocytes overexpressing p75NTR, as compared to mock-
transfected cells. On the other hand, p75NTRsiRNA-transfected keratinocytes fail to 
undergo cell death after administration of NT4 (Truzzi et al., 2010). Interestingly, stem 
keratinocytes (KSC) expresses most of the NGF produced by human keratinocytes (Marconi 
et al., 2004), and inhibition of TrkA reduces the proliferation of this keratinocyte 
subpopulation (Marconi et al., 2004). This suggests that the presence of a NGF-TrkA 
autocrine loop, which acts both as mitogenic and as survival factor, contributing to the 
maintenance of the so-called “stemness” in keratinocytes. Conversely, p75NTR is mostly 
expressed in the differentiated transit amplifying (TA) cells, and it is barely detected in KSC. 
TA cells have been shown to be more susceptible than KSC to apoptosis (Tiberio et al., 2002). 
Therefore, the espression of p75NTR predominantly in TA cells seems to be consistent with 
the pro-apoptotic role of this receptor in human keratinocytes (Truzzi et al., 2011). 
Another important epidermal cell is the melanocyte that localizes in the dermo-epidermal 
junction and in the hair matrix. NTs are important for melanocyte migration, viability and 
differentiation together with other paracrine signalling molecules (Pincelli et al., 1997). 
Normal human melanocytes are a target of the NTs skin network, because they express all 
the NTs receptors both in vitro and in vivo (Marconi et al., 2006). Normal human melanocytes 
also express p75NTR, which is upregulated by different stimuli, like UV irradiation 
(Peacocke et al., 1988). NTs influence melanocytes in a paracrine fashion. NGF is implicated 
in melanocyte survival (Zhai et al., 1996), migration and dendricity (Yaar et al., 1991), and its 
synthesis and secretion are enhanced by UV irradiation (Tron et al., 1990). Moreover, NGF 
reduces apoptosis when melanocytes are irradiated with UV, through upregulation of the 
anti-apoptotic Bcl-2 protein in vivo (Stefanato et al., 2003). Thus, NTs are important for 
protection of UV-induced oxidative stress and apoptosis in melanocytes. Melanocytes 
produce all NTs, while when these factors are added to the cultures, they fail to stimulate 
cell proliferation (Marconi et al., 2006). When melanocytes are maintained in growth factor-
depleted medium, NGF and NT-3 promote melanocyte survival (Yaar et al., 1994). Both NT3 
and NT4 secretion promotes the synthesis of tyrosinase and tyrosinase-related peptide 
(TRP)-1, critical enzyme of melanin biosynthesis (Marconi A et al., 2006). Human 
melanocytes express Trk receptors (Marconi et al., 2006; Yaar et al., 1994). Interestingly, 
phorbol 12-tetra decantate 13 acetate (TPA), a strong activator of protein kinase C, induces 
the expression of TrkA (Yaar et al., 1994) and decreases the expression of TrkC, suggesting 
that NGF and NT3 mediate different signals through their specific high affinity receptors. 
Melanocytes express also the NT low affinity receptor p75NTR, which expression is 
upregulated after TPA treatment (Yaar et al., 1994). 
NTs and their receptors are expressed both in dermal fibroblasts and in the more 
differentiated myofibroblasts. p75NTR and TrkB are expressed at higher levels in 
myofibroblasts than in fibroblasts, which in contrast express higher levels of TrkA. Dermal 
fibroblast and myofibroblasts secrete all NTs, modulating dermal fibroblast proliferation. 
Interestingly, NTs also promote fibroblast differentiation into myofibroblasts, by inducing 
α-SMA expression. This indicates that NTs could have a functional role in the fibro-
myofibroblast system (Palazzo et al., 2011). It has been shown that NGF induces fibroblast-
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like keratinocyte differentiation into myofibroblasts (Micera et al., 2001), their contraction in 
3D collagen matrix (Micera et al., 2001) and the expression of MMP-9 (Metalloprotease-9) in 
keratoconjunctivitis-derived fibroblasts (Micera et al., 2007b), and different works show the 
applicative possibility of this NGF function (Landi et al., 2003; Aloe et al., 2008; Sun et al., 
2010). All NTs promote fibroblast migration, while NGF and BDNF promote their 
contractile activity. Therefore, NGF and BDNF, produced by dermal and epidermal cells, 
could be key regulators of the biomechanical properties in the dermis.  
In the skin network, NT and their receptors are also important for other epidermal cells. 
Skin mast cells express functional TrkA, produce NGF (Marshall et al., 1999), and express 
p75NTR (Fischer et al., 2008). Merkel cells are sensory cells of neural crest origin. During 
development, neither NT-3 nor TrkC and p75NTR are expressed by Merkel cells in the 
murine whisker. However, NT-3 is essential for mice postnatal survival (Szeder et al., 2003). 
Moreover, both TrkB and p75NTR were shown to be important for Merkel cell development 
(Perez-Pinera et al., 2008; Kinkelin et al., 1999).  
 
 
Fig. 2. NTs in the skin network 
4. NTs and the origin of melanoma  
Melanocytes, the cells that originate melanomas, are melanin-producing cells responsible for 
skin, hair and eye pigmentation. The principal role of melanocytes is to protect human skin 
from UVB radiation-induced stress. To understand melanoma origin, it is of paramount 
importance to elucidate the characteristics of the cells that originate the tumor. Indeed, 
melanocytes have intrinsic properties such as migratory capacity and self-renewal, which 
are shared with melanoma cells, and that could be partially responsible for the high 
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susceptibility of melanoma to metastasize and recur in patients. Human melanocytes derive 
from a group of embryonic cells that form, during embryogenesis, the neural crest (NC). 
Neural crest cells (NCC) are multipotent, giving rise to different cell lineages depending on 
their anatomic location, and are therefore referred to as NC stem cells (NCSC). Melanocytes 
appear to derive from both cranial and trunk neural crest, while cells derived from the 
vagal, sacral, mid/hindbrain regions of the crest originate neurons cartilage, bones, smooth 
muscle, peripheral and enteric neurons and glia (Anderson et al., 2000). These multipotent 
cells give rise to a bipotent NCSC that generate both glia and melanoblasts (Dupin et al., 
2000). Although the mechanism of lineage restriction towards melanoblasts specification has 
been deeply studied, it is only partially understood. However, it seems that signals from 
surrounding cells control this mechanism, both during cell homing and in their final 
environment. The bipotent progenitor is able to generate a melanocyte-restricted cell, which 
is referred to as melanoblast. Melanoblasts are unpigmented cells that migrate from the 
neural crest site along the dorsolateral pathway, throughout the developing epidermis. They 
colonize both interfollicular epidermis, localizing at the basement membrane, and 
developing hair follicles. In interfollicular epidermis, melanoblasts differentiate into mature 
melanocytes, upon stimulation from neighbor keratinocytes. In the hair follicle, melanoblast 
can then further segregate into a committed melanocyte or an adult melanocyte stem cell 
(Nishikawa & Osawa, 2007). The committed melanocyte resides in the hair matrix of the 
follicle and differentiates into a melanin-producing cell, thus being responsible for hair 
pigmentation. As opposite, melanocyte stem cells, which reside in the bulge area of hair 
follicles, are amelanotic and conserve characteristics of stem cells such as slow-cell 
cycle/quiescence and self-renewal capacity (Nishimura et al., 2002). The presence of these 
cells ensures the pigmentation of hair follicles in subsequent hair cycles. In humans, 
melanocyte stem cells have not been isolated yet (Sabatino et al., 2009). However, in patients 
affected by vitiligo, a progressive skin disease with defective pigmentation, the 
repigmentation process starts from perifollicular areas, thus implying that, during this 
process, undifferentiated melanocytes in interfollicular epidermis may derive from 
melanocyte stem cells of the hair follicle bulge area (Falabella & Barona 2009). Consistently, 
a migration process of bulge melanoblasts towards interfollicular epidermis has been 
previously observed (Cui et al., 1991). Overall, these observations may suggest that 
melanoblasts in the hair follicles function as a reservoir population both for the bulb hair 
follicle and for interfollicular epidermis.  
Upon UVB radiations and exogenous stress stimuli, melanocytes can acquire genetic 
mutations. Although apoptosis usually eliminates highly damaged mutated cells, some of 
these mutations can confer resistance to apoptosis and proliferative advantage to the cells, 
thus leading to accumulation of mutations and to the formation of melanocytic lesions. The 
old carcinogenesis model, namely “the stochastic model”, suggests that virtually any cell 
could be the target of mutations and subsequent transformation. As opposite, different 
works suggest that only some cells retain the susceptibility to acquire mutations and 
generate cancer, and that these cells can either be differentiated or have stem cells 
characteristics. Whether melanoma arises from melanocyte stem cells or a differentiated 
melanocyte is still matter of debate (Hoek & Godin, 2010). It is possible that differentiated 
melanocytes undergo a process of de-differentiation, thus acquiring stem cell characteristics. 
Melanocyte stem cells in the hair follicle generate an amplifying progeny, which is 
differentiated, still retaining self-renewal capacity. After exiting stem cell niche, transit 
amplifying melanocytes colonize adjacent vacant spaces and repopulate them, thus 
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functioning as stem cells (Nishimura et al., 2002). In quails, melanocytes removed from their 
niche and clonally cultured, can generate multipotent cells retaining self-renewal capacity, 
thus confirming that de-differentiation of melanocytes is indeed possible (Real et al., 2006). 
It has been proposed that melanoma arises in a stepwise process, starting from nevus and 
dysplastic nevus stages to in situ melanoma and finally, to metastatic melanoma. Because 
nevi seems to originate from mutations in a precursor cell, which then activates proliferative 
pathways, while suppressing apoptosis, it would be more likely that melanoma arises from 
a mutated cell with stem characteristics. However, this model does not mimic precisely 
melanoma biology, as melanoma can arise in absence of nevus precursor, and displastyc 
nevi do not necessarily evolve into melanomas (Beona et al., 2003). In many other systems, 
stem cells are considered the best candidate for accumulation of mutations, given their long 
persistence in the tissue and retaining the highest proliferative potential. Although the cell 
at the origin of melanoma is still unidentified, recent works suggest that melanocyte stem 
cells located in the hair bulge may not be the right candidate. Indeed, primary melanoma 
localizes at the junction between dermis and epidermis, suggesting that stem melanocytes 
should migrate from hair follicles to the epidermis before generating melanomas. Moreover, 
while epidemiological studies demonstrate a correlation between melanoma formation and 
UV-radiation-induced sunburn in childhood, hair follicles are only marginally reached by 
UV, because of their deep localization in the tissue. On the other hand, transgenic mice 
overexpressing NRAS and β-catenin develop melanocytic lesion in the follicle bulge, thus 
indicating that melanocyte stem cells in the hair bulge are potentially able to mutate and 
generate melanocytic lesions (Delmas et al., 2007). Up to now, the exact localization of the 
melanoma precursor and the differentiation state of this cell are still unclear. 
Although NCSC contribution to melanoma formation is still controversial, NCSC migration 
during embryogenesis and tumor formation are tightly connected. Indeed, extravascular 
migration process, which guides cells towards their final sites, is shared between melanoma 
cells and NCSC (Lugassy & Barnhill, 2007). In addition, NCSC behavior is influenced by 
NTs and their receptors, which in turn are part of melanoma microenvironment. Epidermal-
restricted NCSC express all NTs, while NGF and NT-3 support their proliferation as well as 
survival of daughter cells, in that NGF and NT-3 depletion results in loss of 70% and 60% 
neurons, respectively (Dasari et al., 2008; Zhang et al., 1997). Moreover, NTs can either 
support proliferation or induce apoptosis in NCC, depending on their 
lineage/differentiation stage (Langtimm-Sedlak et al., 1996). Consistently, different 
expression of trk receptors may identify distinct subpopulations of early NCC. While Trk 
receptors are not expressed at early stages of embryonic development, p75NTR is the first 
NT receptor to be expressed in NCC (Rifkin et al., 2000). NCSC have been previously 
isolated from mouse trunk neural tubes by using a monoclonal antibody against p75NTR. 
p75NTR-positive cells derived from mouse neural tubes are multipotent and have self 
renewal capacity, generating multipotent progeny. These cells can differentiate into smooth 
muscle cells, neurons and glial cells, melanocytes, cartilage and bone. They can also generate 
clonal subpopulations of cells able to generate only glia and neurons, thus suggesting their 
ability to generate also committed progenitors (Stemple & Anderson, 1992). p75NTR, also 
knwon as CD271 (Rogers et al., 2008), was successfully used to isolate multipotent stem cells 
also from rat sciatic nerves (Morrison et al., 1999). These cells generate neurons and glial 
cells when injected into chick embryos, and retain self-renewal capacity.  Multipotent NCSC 
can be isolated from hairy skin in humans and mice (Sieber-Blum & Grim, 2004; Sieber-Blum 
et al., 2004). Consistently, p75NTR-positive cells, isolated from human hair follicle dermal 
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papillae, retain multipotency and contribute to the renewal of neural and non-neural cells, 
including melanocytes (Yu et al., 2006). Recently, multipotent cells with NCSC 
characteristics have been extracted by sphere formation from the dermis of human foreskins 
lacking hair follicles. These cells, not only express stem cells markers such as Oct-4 and 
nestin, but display also multipotency and the ability to differentiate into multiple lineages, 
including melanocytes. Moreover, they express p75NTR, thus suggesting that p75NTR can 
be considered a good marker for NCSC (Li et al., 2010; Paratore et al., 2001).  
Melanoma development is considered a stepwise process in which mature melanocytes in 
the epidermis progressively acquire genetic mutations in oncogenes or tumor-suppressor 
genes that lead from benign to dysplastic nevi, progressing toward radial growth phase to 
vertical growth phase, ultimately followed by metastatic melanoma. Melanomas arise 
within the epidermis and then invade the basement membrane to eventually disseminate to 
multiple organs. During progression, melanoma moves from the epidermal to the dermal 
microenvironment by virtue of various mechanisms that involve different cell types, such as 
keratinocytes, fibroblasts and a number of cytokines and growth factors. While in human 
epidermis, a functional symbiosis exists between keratinocytes and melanocytes, melanoma 
cells are refractory to the regulation by keratinocytes and become independent, by 
autocrinally producing their growth factors (Crowson et al., 2007). The NTs network 
involves most skin cell types and is responsible for various activities. (Botchkarev et al., 
2006). In particular, melanocytes, which share with neurons a common neuroectodermal 
origin, express all NTs and their receptors.  
5. NTs and melanoma  
As for many other growth factors, dysregulation of NT signal transduction is found in a 
number of tumors inside and outside the nervous system where they accompany or 
contribute to malignant transformation (Kruttgen et al., 2006). Yet, the precise role of NTs 
and their receptors has to be clarified (Thiele et al., 2009; Papatsoris et al., 2009). On the other 
hand, NTs have been widely investigated in neuroblastoma (NB) and medulloblastoma, 
tumors derived from the neural crest. Trk-receptors have been identified as important 
prognostic factors, influencing the heterogeneous clinical behavior of NB (Nakagawara, 
1993). TrkA and/or TrkC expression is present in favorable NBs, which tend to show a more 
differentiated neuronal phenotype and highly correlates with patient survival (Nakagawara, 
2001; Brodeur, 2009; Yamashiro, 1996). The tendency of NBs to regress may be related to 
their dependence on an inadequate amount of NGF supplied from stromal cells and a 
differentiating rather than a proliferative response to this NT. Therefore, an autocrine or 
paracrine TrkB/BDNF pathway may contribute to an unfavorable outcome in primary NBs. 
The different clinical implications of the Trk receptors and their isoforms strongly suggest 
that the activation of full-length and truncated TrkA and TrkB may exert different influences 
on the biological behavior of NB cells (Barbacid, 1994). Like NB, medulloblastoma can be 
subdivided in many subtypes with different prognosis (Johnsen et al., 2009). TrkA or TrkC 
has been detected in such areas, in parallel with concentrations of apoptotic or 
differentiating cells (Ohta et al., 2006). TrkC has been correlated to positive prognosis in 
medulloblastoma (Segal et al., 1994) and to apoptosis in vitro in primary medulloblastoma 
(Kim et al.,1999). Nevertheless, the effect of p75NTR on the cellular response to NT is 
complex and may depend on the concentration of ligand, the ratio of receptors, the cell type 
in which it is expressed, and its stage of differentiation (Greene et al., 1995; Chao et al., 
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1995). Overexpression of p75NTR increases the number of high- and low-affinity NGF 
binding sites in TrkA- expressing PC12 cells (Hempstead et al., 1992). Moreover, p75NTR 
induces apoptosis in the presence of NGF (Bunone et al., 1997), but this apoptotic signaling 
is inhibited by the presence of TrkA receptors (Eggert et al., 2000). Recently, it has been 
demonstrated that the effects of necdin, a protein known to interact with NTs receptors, on 
the susceptibility of NB cells to oxidant stress depend on the p75NTR/TrkA ratio in the cell 
(Ingraham et al., 2011). 
Although melanoma is a tumor derived from the neural crest, and shares with cancers of the 
same origin embryogenic and oncogenic pathways as well as common transcription factors 
(Wang et al., 2008; Gershon et al., 2005), it has been given less attention, as far as the role of 
NT. Melanomas can be morphologically subdivided in several subtypes, such as epithelioid, 
pleomorphic spindle cell and desmoplastic melanoma. Iwamoto et al. found detectable 
p75NTR in 13 of 14 benign nevi, primarily in the spindled nevocytic structures within the 
dermis (Iwamoto et al., 2001). Moreover, p75NTR is weakly expressed in the epithelioid 
melanomas, while it is highly expressed in desmoplastic and spindle cell melanomas 
(Iwamoto et al., 1996). This was confirmed by others who showed p75NTR staining to be 
more diffuse and intense as compared with S100 (Kanik et al., 1996; Lazova et al., 2010). On 
the contrary, Huttenbach and co-workers detected p75NTR positive cells only in 33% of 
desmoplastic melanomas (Huttenbach et al., 2002). Marchetti et al, by using melanoma cell 
lines, observed that NGF/p75NTR signaling promotes the survival of melanoma cells 
(Marchetti et al., 2003). They also observed the presence of NGF and NT-3 in tumor adjacent 
tissues at the invasive front of melanoma brain metastases, which might indicate a paracrine 
activation of p75NTR and TrkC in melanoma cells by NGF and NT-3 produced by nearby 
glial cells. Besides promoting melanoma cell survival, NTs also induce the expression in 
melanoma cells of heparanase, an important enzyme for local invasion and metastasis, that 
cleaves heparan sulfate chains of proteoglycans, thus modifying the extracellular matrix of 
tumor cells (Walch et al., 1999). Moreover, Shonukan et al showed that NTs are chemotactic 
for melanoma cells, and that the actin-bundling protein fascin co-immunoprecipitates with 
p75NTR in an NGF-dependent manner (Shonukan et al., 2003). In addition, TrkA is 
expressed by primary and metastatic melanomas and is associated with poor clinical 
outcome (Flørenes et al., 2004). Recently, during a functional characterization of human 
cancer-derived TrkB mutations, one additional TRKB point mutation proximal to the kinase 
domain (TRKB(P507L)) in a human melanoma cell line was found, even if it was 
functionally indistinguishable from wild-type TRKB in both in-vitro and in-vivo (Geiger et 
al., 2011). As melanoma could originate from melanocytes and melanocytes seem to benefit 
from the cutaneous neurotrophic network mainly as paracrine targets, once malignant 
transformation occurs, melanoma cells acquire self-renewal capabilities mediated also by 
autocrine NTs loops. Indeed, all NTs, particularly NT-3 and NT-4, have been detected in 
conditioned medium of different melanoma cell lines (Truzzi et al., 2008). Recent results 
show that melanoma cells proliferate through autocrine NTs stimulation. K252a 
significantly reduces melanoma cell proliferation by inhibiting Trks phosphorylation. 
Proliferation is significantly reduced when endogenous NTs are removed from the culture 
medium by soluble Trk/Fc receptors. NTs appeared to be important for melanoma cell 
migration in vitro, with special respect for metastatic cell lines. The migratory phenotype is 
necessarily dependent on the presence of both the high- and low-affinity NTs receptors. 
Cells treated with p75NTR small interfering RNA (p75NTRsiRNA) fail to respond to NTs 
stimulation. Similarly, the administration of K252a blocks melanoma cell migration, 
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confirming that NTs stimulate melanoma cell migration and invasion with the cooperation 
of the low- and high-affinity receptors (Truzzi et al., 2008). 
 
 
Fig. 3. NTs and their receptors in melanoma biology 
Although melanoma may develop in a stepwise manner from a pre-existing lesion, only 26% 
of melanomas evolve from nevi, while the majority of melanomas arise from normal-
appearing skin, suggesting that melanoma development may not follow the classical linear 
mode of progression (Zabierowsky & Herlyn, 2008). The constant recurrence of melanoma 
after any therapy is likely due to the survival of a subset of cancer cells that display a 
resistance to treatment. The “Cancer Stem Cell hypothesis” states that within tumor 
heterogeneity, only few cells are responsible for tumor initiation and maintenance, sharing 
with normal stem cells the ability to self renew and to persist in the tissue for years. 
Although in some tumors, such as leukemia, the CSC model is valid, in melanoma, cells able 
to initiate tumor formation are not a rare population (Quintana et al., 2010; Held et al., 2010; 
Roesch et al., 2010). Given the role of NTs and their receptors in melanoma biology, this 
complex network of growth factors is likely to be involved both in melanoma recurrence 
and metastasis in the patients. NCSC, that have been proposed as the cells responsible for 
melanoma origin (see above), have been previously isolated both from neural crest and from 
adult tissues by using p75NTR (Kruger et al., 2002). Similarly, Boiko and coworkers showed 
that p75NTR expression characterizes a population of melanoma cells with tumor initiating 
properties (Boiko et al., 2010). However, the number of cells capable of recapitulating the 
tumors in vivo may vary depending on the assay conditions (Quintana et al., 2008). The use 
of sensitive mouse models, such as the NOD/SCID IL2R_(null) mice, demonstrated that cell 
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isolation through p75NTR does not enrich melanoma CSC, and melanoma cells are able to 
metastasize independently from their expression pattern, being able to reverse their 
phenotype through clonal expansion (Quintana et al., 2010; Civenni et al., 2011). 
Consistently, in another study CD34-neg/p75NTR-pos cells from mouse melanomas only 
rarely form tumors, while the p75NTR-negative counterpart frequently forms tumors, 
depending on CD34 expression (Held et al., 2010). This suggests that although some lines of 
evidence point at p75NTR as a good marker for the isolation of melanoma CSC, it may not 
be the right candidate. It is interesting to mention though that the frequency of p75NTR-
positive cells in melanoma samples correlates with higher metastasis and worse patient 
prognosis (Civenni et al., 2011). Altogether, these results suggest that p75NTR-positive cells 
are not the CSC population in melanoma, but may retain characteristics of aggressiveness 
and susceptibility to metastasize. Further characterization of these cells and evaluation of 
the role of p75NTR in melanoma stem cells is still needed.  
6. Conclusions  
A significant progress in understanding NTs signaling in skin has been done during the last 
fiftheen years. Although more studies are needed to better elucidate the role of these 
molecules in cutaneous physiology and pathology, there is a large body of evidence 
indicating that NTs form a complex network with autocrine and paracrine functions. In this 
context, NTs and their receptors seem to play an important role in the origin, development 
and invasiveness of malignant melanoma. Given the premise and the common 
neuroectodermal origin of the skin and the nervous system, future studies will allow a 
better understanding of the cell of origin of melanoma and of the environment that favors 
the growth and metastasis of the tumor. Translating these data into clinically oriented 
research will possibly unravel novel strategies for the treatment of melanoma. In particular, 
blocking Trks will inhibit melanoma cell migration and survival, thus acting in a less toxic 
and more specific manner, as compared to chemotherapy. Interestingly, Lestaurtinib (CEP-
701), a Trk-selective inhibitor, is effective and well tolerated in patients with refractory 
neuroblastoma (Minturn JE et al., 2011; Evans AE et al., 2001). In addition, inhibitors of Trk 
kinase activity, such as K-252a family members, have a significant anti-tumor activity in 
prostatic and pancreatic carcinomas, in preclinical studies.   
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